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CHAPTER I 
INTRODUCTION 
Malaria as a Global Threat 
Malaria continues to be a serious threat to human health around the world. Taken from 
the World Health Organization’s (WHO) recent World Malaria Report, there were an estimated 
212 million cases and 429,000 deaths in 2015. Even with the $2.9 billion dollars pumped into the 
fight against malaria, there are still 91 countries and territories where the disease is considered to 
be endemic. Around 90% of the cases worldwide occurred in the WHO African Region with the 
remaining cases occurring in the WHO South-East Asia and Eastern Mediterranean Region. The 
WHO also found that only 30% of the population who is most at risk, children under the age of 
5, received an antimalarial drug when testing positive for malaria infection. 
The Malaria Parasite, Plasmodium 
Malaria is a vector-borne disease that is caused by a protozoan, Apicomplexan parasite of the 
genus Plasmodium. There are five known species of Plasmodium that can infect humans: P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Of these five species, P. falciparum 
is the most prevalent species in Africa, causing the most severe form of the disease, and 
consequently producing the highest mortality rates (Miller et al., 2002). P. vivax can also cause 
symptoms such as anemia; however, P. vivax is less virulent and not as widespread in the 
African region. Most of the Plasmodium species are transmitted by the bite of an infected female 
Anopheles mosquito (Oaks et al., 1991).  
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When an infected female mosquito takes a blood meal on a person, she injects invasive 
sporozoites from her salivary glands. The sporozoites travel through the bloodstream to the liver 
where they invade hepatocytes. Within the liver cells and over the course of 5-15 days, the 
sporozoites undergo schizogony and develop into tens of thousands of merozoites. The liver 
stage schizonts burst and release the merozoites into the bloodstream where they can then infect 
erythrocytes and continue reproducing asexually. Inside the erythrocyte, the merozoite continues 
to develop within a parasitophorous vacuole membrane (PVM) that consists of the membrane 
bilayer of the RBC. Over the course of 24-48 hours, the merozoite develops into a trophozoite 
and again undergoes schizogony. The schizont bursts and releases 10-20 merozoites into the 
blood where they infect new erythrocytes, continuing a cycle that causes the destruction of more 
RBCs and ultimately results in the symptoms that are characteristic of malaria (Miller et al., 
2002) (Figure 1 RIGHT).  
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A small subset of the parasite population will exit the asexual blood cycle and commit to 
sexual development. Instead of undergoing schizogony, the merozoites will develop into distinct 
male and female gametocytes. When a mosquito takes up these gametocytes with a blood meal, 
the gametocytes complete sexual reproduction within 15 minutes of entering the mosquito 
midgut. The female gametocyte egresses from the RBC and forms a macrogamete while the male 
gametocyte undergoes three rounds of DNA replication and releases eight exflagellating 
microgametes. The microgametes fertilize the macrogametes to generate a diploid zygote (Figure 
1 LEFT). 
Still part of the mosquito blood meal, the zygote develops into a motile form, called an 
“ookinete,” over the course of the next 18-24 hours (Figure 1 LEFT). The parasite elongates into 
a polar, banana shape that enables the ookinete to pass through the blood meal and invade the 
epithelial lining of the midgut. The ookinete settles under the basal lamina of the midgut 
epithelial wall and undergoes multiple rounds of DNA replication and mitosis. Following a large 
scale cytokinesis event, the resulting oocyst contains thousands of haploid sporozoites. After 8-
15 days, the oocyst bursts and releases motile sporozoites that travel to the mosquito salivary 
glands. Within the salivary glands, the sporozoites are primed for transmission and will be 
injected in to the next host during the mosquito’s next blood meal (Oaks et al. 1991). 
As drug-resistant parasite strains and insecticide-resistant mosquitoes are becoming more 
prevalent (Tun et al. 2015; WHO, 2010), research has been shifting towards the design of novel 
transmission blocking strategies. However, the only current transmission blocking vaccine 
candidate shows very little potential for long term protection and only targets one stage of the 
complex malaria parasite’s life cycle (Gosling & Seidlein, 2016). As most of the research done 
on malaria focuses on development within the human host, very little is known about parasite 
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cell biology during mosquito stage development. In an effort to better understand and target 
Plasmodium transmission, our lab is currently studying the adaptive mechanisms underlying 
parasite survival and development, specifically in the mosquito vector. 
The Model Rodent Malaria Parasite, Plasmodium berghei  
The murine malaria parasite, Plasmodium berghei, has been established in the research 
community as an excellent model system for studying the mosquito stages of Plasmodium 
(Sinden, 1978). The P. berghei life cycle and morphological characteristics are comparable to 
those of the human parasite, Plasmodium falciparum (Sinden, 1978). The genome organization 
and metabolic pathways are also largely conserved between the rodent malaria parasites and the 
human malaria parasites (Janse et al., 1994; Janse and Waters, 1995). On top of sharing many 
genetic and physical features, P. berghei can easily be used to study Plasmodium within the 
mosquito vector. As P. berghei is not infectious to humans, mosquitoes can be safely infected 
and studied in the laboratory. Working with mice is also much simpler and carries less ethical 
implications than working with humans.  
Survival in the Mosquito Midgut 
Upon arrival in the mosquito midgut and egress from the protective membrane of the 
RBC, Plasmodium becomes vulnerable in the inhospitable environment of the bloodmeal. Here, 
the parasite is exposed to an increased pH, a decreased temperature, the mosquito’s own 
mounted immune response, digestive enzymes (Alavi et al., 2003), reactive oxygen species 
(ROS), reactive nitrogen species (RNS), and a diverse microbial flora (Müller, 2004; Fang, 
2004). As a result of these stressors, the mosquito acts as a bottleneck for Plasmodium where 
only very few parasites survive (Smith et al. 2014; Wang and Jacobs-Lorena 2013).  
 
		
5 
Defense Systems 
Within the mosquito midgut, Plasmodium must defend itself from the harsh conditions, 
including cytotoxic ROS. Using one of the main antioxidant systems, the thioredoxin system, the 
parasite generates an environment in which it can cope with the oxidative stressors (Kanzok et 
al., 2000).  
Thioredoxins and thioredoxin-like proteins comprise a large superfamily of proteins. 
Some of the proteins are ubiquitous redox proteins that play essential roles in many biological 
processes, such as the detoxification of reactive oxygen and nitrogen species and the redox 
regulation of protein function and signaling (Arner and Holmgren, 2000). Thioredoxins 
exchange electrons via the reduction/oxidation of dithiol/disulfide bonds, which maintains their 
cellular targets in a reduced state (Arner and Holmgren, 2000).  
Within the thioredoxin superfamily, only a few proteins, such as Thioredoxin-1, have 
been well characterized (Nakao, 2015). Our lab has been studying the thioredoxin system of 
Plasmodium and searching for novel thioredoxin-like proteins that could play a role during 
parasite development in the mosquito. 
Escape from the Midgut 
Plasmodium must escape the midgut to avoid digestion with the rest of the bloodmeal. 
The parasite accomplishes this by developing into a polar, motile ookinete (Figure 2). This 18-
hour transformation enables Plasmodium to traverse the epithelial cell lining of the midgut and 
move out of the harsh environment (Oaks et al., 1991). Without the ability to move and invade 
the epithelial cells, the parasites would fail to establish infection of the mosquito and would be 
digested with the rest of the bloodmeal.  
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A complex network of cytoskeletal organelles and filaments located underneath the 
plasma membrane, called the inner membrane complex (IMC), facilitates the polarity and 
motility (Baum, 2006).  Plasmodium motility is driven by an actin-myosin based motor that is 
anchored in the IMC (Baum, 2006). The distinctive shape of the ookinete is maintained by a 
twisted lattice of subpellicular microtubules that are associated with the IMC (Baum, 2006). 
These subpellicular microtubules are lined with proteins that stabilize and maintain the function 
of the microtubules. To date, very little is known about these microtubule associated proteins 
(MAPs) in Plasmodium ookinete biology. Some have been studied in the merozoite and 
sporozoite invasive stages and are primarily based on studies from related Apicomplexan 
parasites, such as Toxoplasma gondii.  
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Homology in a Related Apicomplexan Parasite, Toxoplasma gondii 
Like Plasmodium, Toxoplasma gondii is a protozoan parasite and is a member of the 
phylum Apicomplexa. It is the causative agent of toxoplasmosis in humans. T. gondii replicates 
primarily in cats and can also survive in a variety of intermediate warm-blooded hosts, such as 
pigs and bird. T. gondii has been previously established as a good model for understanding 
Apicomplexan biology (Kim and Weiss, 2004; Baum et al., 2008). However, there are notable 
differences between T. gondii and Plasmodium. Plasmodium specifically infects hepatocytes and 
the red blood cells of its mammalian hosts, whereas T. gondii invades all nucleated cells and 
eventually infects many tissues, including the CNS, muscles, and placenta (Montoya and 
Liesenfeld, 2004). Additionally, while T. gondii is transmitted by contaminated food, water, 
infected faeces or tissues of warm blooded animals, Plasmodium is transmitted solely by 
mosquitoes. Keeping these distinct differences in mind, we can use the studies in T. gondii to a 
certain degree to inform our own hypotheses about Plasmodium biology.  
Genes of Interest 
trxl-1 
 As one of the major defense systems in Plasmodium, our lab studies the thioredoxin (trx) 
system and its potential cellular targets. We previously identified a novel P. berghei 
Thioredoxin-like protein, TrxL-1 (David et al., in prep) that is conserved across Apicomplexans 
where the closest P. berghei relative is T. gondii (Figure 3A) While the N and C terminus of 
TrxL-1 vary across species, there is a notably high level of conservation among the Trx-like 
domains (Figure 3B). Our initial biochemical characterization shows that the TrxL-1 protein is 
redox active and can interact with the thioredoxin system of Plasmodium in vitro. Despite its 
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redox activity, TrxL-1 shows very low levels of ROS reduction and therefore cannot be 
classified as an antioxidant enzyme.  
 
Characterization of the expression profile of trxl-1 included RT-qPCR and was carried 
out by previous members of our lab (David et al. in prep). Relative transcript levels were 
examined in the blood stages and mosquito stages. The RT-qPCR data indicates that the trxl-1 
transcript is absent during parasite development in the mouse blood and highly upregulated 
during mosquito stage development (Figure 4A).  
The data also reveals a 10-fold increase in trxl-1 transcript abundance within the 
mosquito midgut when compared to the abundance in culture (Figure 4B).  As the highest level 
of trxl-1 transcript is observed during ookinete development, this suggests that trxl-1 is involved 
in early mosquito stage development.  
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Notably, a recent study found that the T. gondii homolog, TgTrxL-1, is associated with 
subpellicular microtubules (Liu et al., 2013). Futhermore, TgTrxL-1 localizes to the 
microtubules but does not directly affect microtubule stability. Because of our initial results on 
trxl-1 and the findings in T. gondii, I decided to study the Plasmodium trx-l gene in this thesis. 
spm-1  
In the same T. gondii study described above (Liu et al. 2013), it was found that TgTrxL-1 
indirectly interacts with the subpellicular microtubules via other proteins, prominently the 
subpellicular microtubule protein-1 TgSPM-1 (Tran et al., 2012). Because of these findings, I 
also chose to study the Plasmodium spm-1 gene in this thesis. 
Unlike the mosquito specific expression of trxl-1, the expression profile data on spm-1 
taken from the Plasmodium genome database, PlasmoDB, shows an increase in transcript level 
during gametocytes (Aurrecoechea et al., 2009). Additionally, the SPM-1 protein contains a 
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conserved domain, the STOP (Stable Tubule Only Polypeptide) domain (Finn et al., 2017). 
STOP proteins have been known to function as MAPs that are involved in the stabilization of 
axonemal microtubules by conferring cold resistance (Delphin et al., 2012). An SPM-1 homolog, 
called STOP Axonemal protein-1 (SAXO-1), has been found to be involved in flagellum motility 
in another vector-borne protozoan parasite, Trypanosoma brucei (Dacheux et al., 2012).  
Using the data that our lab has accumulated on trxl-1 together with the published data 
from the T. gondii studies on spm-1, I hypothesize that trxl-1 and spm-1 play an important 
role in ookinete development, specifically in the stabilization of the subpellicular 
microtubule network.  
To investigate the cellular functions of trxl-1 and spm-1, I decided to generate gene 
knockout (KO) parasite lines. However, most of the methods used to modify the Plasmodium 
genome are time-consuming and inefficient (Straimer et al. 2012). At the time that I started my 
thesis, the CRISPR/Cas9 system had just been used in P. falciparum (Wagner et al. 2014) and P. 
yoelii (Zhang et al., 2014) to specifically edit these parasite genomes. Because of their success, I 
decided to adapt the CRISPR/Cas9 system to P. berghei. 
CRISPR/Cas9 Genome Editing System  
The CRISPR/Cas9 gene editing system has been developed as an efficient technology 
that can make precise changes to the genome. It has been successfully used to manipulate the 
genome of many organisms (Cong et al. 2013; Mali et al. 2013). It is based on Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) that act as a bacterial defense 
against invading viruses. CRISPR was transformed into a gene editing technology that can be 
used to target any locus of interest in the genome via an RNA-directed endonuclease, Cas9 
(Figure 5). The small guide RNA (sgRNA) is co-transcribed and forms a complex with Cas9. 
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When the sgRNA aligns with its complement in the genome, Cas9 induces a double strand break 
(DSB) in the DNA. This DSB is either repaired with the nonhomologous end joining pathway 
(NHEJ) or homology directed repair (HDR).  
 
As this system enables the introduction of efficient, specific changes in any gene, it is an 
incredibly powerful and valuable tool for Plasmodium research. CRISPR/Cas9 has been 
previously established in other Plasmodium species, including the human parasite P. falciparum 
and the rodent parasite P. yoelii. (Wagner et al., 2014; Zhang et al., 2014) As CRISPR/Cas9 has 
not been established in the rodent model parasite P. berghei, I am the first to use this system in 
this malaria model. In this study, I investigated the function of two novel P. berghei genes via 
Cas9-mediated gene knockout. 
Thesis Objective 
 Very little is understood about Plasmodium biology within the mosquito vector. The 
objectives of this project were to establish the CRISPR/Cas9 system in Plasmodium berghei and 
investigate the function of two novel mosquito specific genes, trxl-1 and spm-1. The results 
presented in this thesis shed light on the molecular mechanisms that the malaria parasite utilizes 
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to survive in the mosquito and ultimately establish infection of the mosquito. While current 
malaria treatment and prevention strategies target the parasite in the human host, these data have 
the potential to inform novel transmission blocking strategies in the mosquito vector.
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CHAPTER II 
MATERIALS AND METHODS 
Reagents 
All PCR primers, oligos, enzymes, and corresponding enzyme buffers were obtained from 
Thermo Fisher Scientific (Waltham, MA).  
 
Amresco; Solon, OH: glycerol, sodium dodecyl sulfate (SDS), tris. 
 
Bioexpress; Kaysville, UT: 10X phosphate buffered saline (PBS), agar, fetal bovine serum 
(FBS), nuclease free water, tryptone, urea. 
 
Growcells.com; Irvine, CA: X-Gal Powder. 
 
Lonza; Basel, Switzerland: Nucleofector Kit T. 
 
Molecular Research Center, Inc.; Cincicannati, OH: Tri-Reagent RT. 
 
Open Biosystems; Huntsville, AL: anti-Thioredoxin rabbit serum. 
 
Promega; Madison, WI: dithiothreitol (DTT), JM109 Competent Cells, pGEM-T Easy Vector 
System. 
 
Sigma-Aldrich; St. Louis, MO: ethylenediaminetetraacetic acid (EDTA), Giemsa, Heparin 
sodium salt, nycodenz, paraformaldehyde, penicillin-streptomycin, phenylhydrazine, proteinase 
K, pyrimethamine, RPMI-1640 medium, saponin, triton X-100, tween 20. 
 
Southern Biotech; Birmingham, AL: DAPI Fluoromount-G. 
 
Thermo Fisher Scientific; Waltham, MA: 6X DNA Loading Dye, Alexa Fluor 488 Goat anti-
Rabbit IgG, Alexa Fluor 555 Goat anti-Mouse IgG, ampicillin trihydrate, bovine serum albumin 
(BSA), boric acid, dimethyl sulfoxide (DMSO), DreamTaq PCR Master Mix, Ethidium Bromide 
Solution, GeneJET Gel Extraction Kit, GeneJET Whole Blood Genomic DNA Purification Mini 
Kit, GeneJET PCR Purification Kit, GeneJET Plasmid Miniprep Kit, GeneRuler 1 kb Plus DNA 
Ladder, glacial acetic acid, glycine, hydrochloric acid (HCl), isopropyl 𝛽-D-1-
thiogalactopyranoside (IPTG), methanol, magnesium chloride (MgCl2), potassium phosphate 
(KH2PO4), sodium borohydride, 
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sodium chloride (NaCl), sodium hydroxide (NaOH), sodium phosphate (Na2PO4), TopVision LE 
GQ Agarose, yeast extract. 
 
Whatman; Dassel, Germany: Reinforced Nitrocellulose Membrane.  
Buffers, Media, and Solutions 
10X TBE Electrophoresis Buffer: 108 g Tris base, 55 g boric acid, 40 mL 0.5 M EDTA (pH 8.0), 
dH2O to 1L.  
 
Freezing medium (blood stocks) 20% Glycerol: 10 mL glycerol, 5 mL 10X PBS, 35 mL nuclease 
free water. Filter sterilize. 
 
Freezing medium (bacterial stocks) 50% Glycerol: 25 mL glycerol, 5 mL 10X PBS, 20 mL 
nuclease free water. Filter sterilize. 
 
50X TAE Electrophoresis Buffer: 242 g Tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 M 
EDTA (pH 8.0), dH2O to 1L.  
 
Blocking Buffer: 3% BSA in PBST. 
 
Luria-Bertani (LB) Medium: 5 g yeast extract, 10 g NaCl, 10 g tryptone, 1L dH2O. Sterilize by 
autoclaving.  
 
Ookinete Culture Medium: RPMI-1640, 20% FBS, 1% pen-strep, pH 8.2. Filter sterilize. 
PBST: 1X PBS, 0.1% Tween 20, pH 7.2. Sterilize by autoclaving. 
Pyrimethamine Solution (7mg/mL): 70 mg pyrimethamine, 10 mL DMSO. Dissolve 
pyrimethamine in DMSO via vortexing. Dilute 100X with tap water for final volume of 1L. 
Adjust pH to 3-5. Store at 4 degrees for 7-10 days. 
 
Shizont Culture Medium: RPMI-1640, 20% FBS, 1% pen-strep, pH 7.2. Filter sterilize. 
Accession Numbers 
Protein Name PlasmoDB Accession Number 
Thioredoxin 1 (Trx1) PBANKA_1320900 
Thioredoxin Reductase (TrxR) PBANKA_0824700 
Thioredoxin-like Protein-1 (TrxL1) PBANKA_0820200 
Subpellicular Microtubule Protein 1 (SPM1) PBANKA_0810700 
1-Cysteine Peroxiredoxin (1-Cys Prx) PBANKA_122800 
      Table 1. Accession numbers for all genes examined. 
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Ethics statement 
All experimental protocols followed the National Institutes of Health guidelines for 
animal housing and care and were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Loyola University Chicago (Protocol#1429/40). 
Parasite Maintenance 
Plasmodium berghei ANKA 2.34 wild type (WT) parasites were maintained in outbred 
Charles River strain CF1 mice. After a maximum of six passages, the parasites were passed 
through Anopheles stephensi mosquitoes and subsequently kept at 19°C, 80% RH, 12 hrs light-
dark cycle, 5%glucose solution.  On day 17 post infectious blood meal (PIBM), the mosquitoes 
were allowed to feed on naïve mice for 15 minutes. The new generation of parasites were 
harvested when the mice reached ~30% parasitemia (percent infected RBCs). Blood stocks of P. 
berghei parasites were stored at -80°C in 20% glycerol in phosphate-buffered saline (PBS).  
Mosquito Maintenance 
 Anopheles stephensi mosquitoes were reared under standard conditions in the insectary 
(26°C, 80% RH, 12 hrs light-dark cycle). The mosquito colony was maintained by allowing one 
bucket of at least one week old mosquitoes to feed on mice once a week. Two days post feed, an 
egg cup was placed in the bucket where the female mosquitoes lay their eggs and three to six 
new pans were set to equilibrate. Three days post feed, eggs from the egg cup were transferred to 
the equilibrated pans. Larvae were fed daily until pupation. All mature pupae were transferred to 
a new bucket in a small cup. Once the pupae emerged, the mosquitoes were provided with a 5% 
glucose feeding solution in a cup with filter paper. 
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Exflagellation 
 The egress and subsequent exflagellation of the male gametocytes is measured in vitro 
via live bright field microscopy. 2 uL of infected mouse tail blood is incubated in 2 uL heparin 
and 50 uL ookinete culture medium at 19°C for 15 minutes. 10 uL of each sample is added under 
the cover slip of a hemocytometer. The number of exflagellating cells are counted per 20X field. 
Ookinete Cultures 
For the enrichment of gametocytes, mice were pretreated with phenylhydrazine (Phz) 2 
days before injecting blood stage parasites. Exflagellation rates were checked 2 days post-
infection. The blood was harvested when exflagellation reached >10 exflagellations/20X field. 
The blood of infected mice was pooled, diluted 1∶5 with ookinete culture medium (RPMI-1640, 
pH 8.2), and incubated at 19°C for 24 hrs.  
Infectious Mosquito Feeds 
Similar to the ookinete cultures, mice were pretreated with phenylhydrazine (Phz) 2 days 
before injecting blood stage parasites. Exflagellation rates were checked 2 days post-infection. 
Once the exflagellation reached >10/20X field, female Anopheles stephensi mosquitoes were 
allowed to feed on the infected mice for 15 minutes. The bloodfed mosquitoes were subsequently 
stored in an environmental chamber kept at 19°C, 80% RH, 12-hour light-dark cycle, 5% glucose 
solution. 
Isolation and Purification of P. berghei genomic DNA 
Genomic DNA (gDNA) was extracted from 200 uL of whole blood of the infected mice. 
The GeneJET Whole Blood Genomic DNA Purification Mini Kit was used to perform cell lysis 
and subsequent DNA purification. DNA concentration and purity was assessed using the 
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FLUOstar Omega plate reader (BMG Labtech; Cary, NC). All gDNA samples were stored at -
20°C. 
CRISPR/Cas9 design and Plasmid Construction 
The TrxL-1 KO and SPM-1 KO plasmids were generated using the plasmid pYC (for 
plasmid for yoelli containing Cas9) which was a kind gift from Jing Yuan, Xiamen University, 
Xiamen, Fujian, China. The PyU6 promoter driving the sgRNA cassette was replaced with a 
Plasmodium berghei specific U6 snRNA promoter (PbU6) that was amplified from P. berghei 
ANKA genomic DNA (Primers in Table 2). The P. berghei specific plasmid was named pBC 
(plasmid for berghei containing Cas9).  
The 20bp target sequence (TS) for each gene of interest was determined using Geneious 8 
(https://www.geneious.com, Kearse et al., 2012). The annealed oligonucleotide TS for trxl-1 was 
inserted into the BsmBI restriction site. Due to difficulties in the ligation of the trxl-1 TS, the 
spm-1 TS was designed into the forward primer of a primer set that amplified the sgRNA using 
pBC as the template. The resulting spm-1 TS-sgRNA product was inserted into pBC and 
replaced the empty sgRNA scaffold.  
For the generation of a targeted and easily detectable gene deletion, a homology template 
for Homology Directed Repair (HDR) of each gene of interest was designed in the pCR4-TOPO 
TA Vector (a generous gift from Kim Williamson, Uniformed Services University) based on 
previously described methods [3]. The 5’ and 3’ genomic regions flanking each gene of interest 
were amplified from PbWT genomic DNA and successively inserted on each side of a short 
disrupter. The complete 5’UTR-Disrupter-3’UTR homology construct was inserted into the 
HindIII restriction site on pBC. The finished TrxL-1 KO plasmid was named pBCT (plasmid for 
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berghei containing Cas9 for trxl-1 KO) and the SPM-1 KO plasmid was named pBCS (plasmid 
for berghei containing Cas9 for spm-1 KO).  
Polymerase Chain Reaction (PCR) 
All PCR reactions were incubated on the Eppendorf Mastercycler ep gradient S thermal 
cycler. The primers used for the amplification of the PbU6 promoter, TrxL-1 5’ UTR and 3’ 
UTR, SPM-1 5’ UTR and 3’ UTR, TrxL-1 target sequence, SPM-1 target sequence and guide 
RNA, gene disrupter, and sequencing reactions are listed in Table 2.  
  Table 2. PCR Primers. 
 All reactions were set up using the general guidelines as follows:  
5 uM forward primer,  
5 uM reverse primer,  
750 ng gDNA template,  
1X DreamTaq PCR Master Mix  
Nuclease free water up to a final volume of 20 uL 
Target Fwd Primer Sequence 5’ à 3’ Rev Primer Sequence 5’ à 3’ Amplicon 
PbU6 P1 GGCGCCCTCTACTTCACGCAAATGTAACAC P2 
CATATGTATAACTCGAAGTAT
GCGCATATG 337 bp 
TrxL1  
5’ UTR P3 
GGATCCGCAAGCTTGGATGTGT
TAAGTGTATTATGGATGGC P4 
GGATCCCCATTTAAACTATTAT
GTTC 359 bp 
TrxL1 
3’ UTR P5 
TCTAGAACATATTTGCCAATGT
GGAGAACG P6 
TCTAGAGCAAGCTTCTTATACT
TTATTTCATCCC 361 bp 
SPM1 
5’ UTR P7 
GGATCCGCAAGCTTAACATTTT
ACAGAAATATGCAGC P8 
GGATCCCATCTATGAAAGCCA
CACGT 690 bp 
SPM1 
3’ UTR P9 
TCTAGACAGCTGAACATATATT
TTGGG P10 
TCTAGAGCAAGCTTATACGTG
CATTTCTTAGCGTTTCC 497 bp 
Sequencing 
Homology 
Constructs 
P11 AATTTCACACAGGAAACAGC P12 GCACAATATCTAGGATACTAC ----- 
TrxL1 TS P13 GTTTTTAGTCGTTATCGGAAGTGA P14 
AAACTCACTTCCGATAACGAC
TAA ----- 
SPM1 TS-
sgRNA P15 
TCAGCTGGATAAGTAGGTGCGT
TTTAGAGCTAGAAATAGCAAG P16 TGACGTCCAAAAAAAGCACC 150 bp 
Gene 
Disrupter P17 GGATCCACTAGTAACGGCCG P18 GCTAGCTACGAAGGGCGAAT ----- 
Sequencing 
TrxL1 P19 
TTGCTAATTTTTTGTGAGCAGA
CC P20 
CAATCGCACATGCACGTATTC
G ----- 
Sequencing 
SPM1 P21 
GACTGTTTATTTTAAAGCACAT
TG P22 
GCATAATTCATTCAATCGATTT
CC ----- 
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All reactions were incubated in the ThermoCycler with the following program:  
 Initial Denaturing: 10 minutes at 95°C 
 
Denaturing: 30 seconds at 95°C 
 Annealing: 30 seconds at 56°C - 60°C 35 Cycles 
 Elongation: 30 seconds – 3 min at 72°C 
 
 Final Elongation: 5 minutes at 72°C 
The primer annealing temperature was determined first by subtracting 5 degrees from the 
melting temperature provided. If the reaction did not work, a gradient was set up to determine 
optimal annealing temperature for the primer sets. The elongation time was determined by the 
length of the desired PCR product following the convention that the polymerase runs at about 1 
kb per minute.  
If the gradient did not prove successful, the concentration of magnesium chloride was 
increased due to the difficult template. Increasing magnesium chloride concentration improved 
the genomic DNA amplification where there is a high AT content. 
DNA Electrophoresis 
Depending on their size, all DNA fragments were run out on a 0.8% - 1.2% agarose gel 
containing 0.5 ug/mL ethidium bromide. If the samples did not already contain loading dye, 6X 
DNA loading dye was added to a final concentration of 1X. GeneRuler 1 kb Plus DNA Ladder 
was used to determine DNA fragment size. The gel was run in 1X TAE buffer at 110V for 40 
minutes using the Owl Horizontal Gel Electrophoresis System (Thermo Fisher Scientific; 
Waltham, MA). The DNA bands were visualized under UV light and subsequently extracted 
with the GeneJET Gel Extraction Kit.  
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TA Cloning of PCR Products into pGEM 
 The pGEM-T Easy Vector System II was used with the gel extracted PCR products. The 
reagents were used in the following concentrations: 1X Rapid Ligation Buffer, 25 ng pGEM-T 
Easy Vector, 3 units T4 DNA Ligase, PCR product 3-5 times more concentrated than the vector, 
and nuclease free water up to 10 uL. The ligation was incubated overnight at 4°C. 
Transformation of JM109 E. coli Competent Cells 
 2 uL of a ligation mixture was gently mixed with 25 uL of competent cells in a 1.5 mL 
microcentrifuge tube. The cell-ligation mixture was incubated on ice for 20 minutes. The cells 
were heat shocked at 42°C for 45 seconds and placed on ice for 2 minutes. 275 uL of LB 
medium was added to the cells and incubated in a shaking incubator at 37°C for 1 hour. The 
resulting transformed cells were spread on pre-warmed LB/agar plates containing 0.1 mg/mL 
ampicillin. 
If transforming a pGEM ligation, blue/white screening was also used. Before addition of 
the transformed cells, 0.1 mM IPTG and 20 ug/mL X-Gal was spread onto the LB/agar plates 
and allowed to absorb. Once the cells soaked into the plate, the plate was inverted and incubated 
at 37°C overnight. 
Restriction Digests 
 Restriction digests for each desired fragment were set up using the enzymes listed in 
Table 3. The reactions were set up according to the manufacturer’s instructions using each 
enzyme’s recommended buffer. The digests were incubated for at least 2 hours (up to overnight) 
at 37°C and subsequently run out on a 0.8% - 1.2% agarose gel. If a fragment was to be inserted 
into a vector, the digested vector was dephosphorylated using a Calf Intestinal Alkaline 
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Phosphatase (CIAP) before running the sample on the gel. The correctly sized DNA fragments 
were cut out and purified via gel extraction.  
Primer Set Forward Reverse Fragment Size 
PbU6 KasI NdeI 337 bp 
TrxL1 5’ UTR BamHI, HindIII BamHI 359 bp 
TrxL1 3’ UTR XbaI XbaI, HindIII 361 bp 
SPM1 5’ UTR BamHI, HindIII BamHI 690 bp 
SPM1 3’ UTR XbaI XbaI, HindIII 497 bp 
SPM1 TS-sgRNA NdeI AatII 150 bp 
                Table 3. Restriction Enzymes. 
Ligations of DNA Fragments into a Vector 
 Ligations into vectors other than pGEM were set up using 1X T4 DNA Ligase Buffer, 1 
unit T4 DNA ligase, and varying ratios of insert to vector where there was always at least 2X 
more insert than vector. The reaction was incubated at room temperature for 2 hours or overnight 
at 4°C.  
DNA Isolation, Purification, and Concentration 
 Precultures with transformed bacterial colonies were set up with 1 colony in 5 mL LB 
medium and 5 uL of 100 mg/mL ampicillin. The precultures were incubated overnight in a 37°C 
shaker and pelleted the following day. Plasmids were isolated from the bacteria and purified 
using the GeneJET Plasmid Miniprep Kit. If necessary, the plasmid DNA was precipitated and 
concentrated using ethanol. 0.1 volumes of 3M sodium acetate and 3 volumes of ice cold 100% 
ethanol was added to the DNA and mixed via vortexing. The DNA was allowed to precipitate for 
at least 1 hour at -20°C and pelleted at 13000 rpm at 4°C for 30 minutes. The pellet was washed 
twice with 500 uL ice cold ethanol and spun down at 4°C for 10 minutes after each wash. The 
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ethanol was carefully removed and allowed to dry. The pellet was resuspended in an appropriate 
volume of nuclease free water. 
Generation of Transgenic Parasites 
All transgenic parasite lines were generated from Plasmodium berghei ANKA wild type 
(PbWT) parasites. Each plasmid (pBC, pBCT, and pBCS) was transfected following previously 
described methods (Janse et al., 2006).  
Schizont Culture and Purification 
A naïve mouse was infected with PbWT parasites from a frozen blood stock. The 
infected mouse was then exsanguinated and passed into 2-4 new mice. When the mice reached a 
parasitemia of 1-3%, they were exsanguinated and the blood was added to 10 mL of schizont 
culture medium supplemented with heparin. The blood was spun down at 500xg slowly and the 
supernatant was discarded. The blood was resuspended in fresh schizont culture medium and 
transferred to tissue culture flasks. The cultures were incubated overnight at 37°C with 5% CO2 
and 3% O2.  
The cultures were harvested when around 80% of the schizonts were mature with 8-14 
merozoites per cell. The blood was gently layered on top of a 17% Nycodenz layer and 
centrifuged slowly at 500xg for 20 minutes. The interface between the layers that contains the 
mature schizonts was collected with a Pasteur pipet, transferred to a fresh tube, and 
supplemented with fresh culture medium. The collected schizonts were again centrifuged at 
500xg for 10 minutes. The supernatant was removed, and the pellet was resuspended in enough 
media to aliquot 1 mL of resuspended schizonts per 1 injection. The aliquoted schizonts were 
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briefly centrifuged for 5 seconds at 17,000xg. The supernatant was removed and the pellet was 
immediately used for transfection. 
Transfection of P. berghei 
The plasmids were transfected into P. berghei schizonts using the Nucleofector kit T 
(VCA-1002; Lonza, MD). 80 uL of the Nucleofector Solution and 20 uL of the Nucleofector 
Supplement were added to 10 uL of linearized plasmid DNA at a concentration of .5 - 1 ug/uL. 
100 uL of the DNA mixture was used to resuspend 1 pellet of aliquoted schizonts. This cell 
suspension was quickly transferred to an electroporation cuvette and inserted into the Amaxa 
Nucleofector I Electroporator (Amaxa Biosystems; Cologne, Germany). Electroporation was 
carried out using program U33.  
Immediately following electroporation, the cells were supplemented with 50 uL of fresh 
pre-warmed schizont culture medium. The 150 uL of transfected cells was then directly injected 
into the tail vein of naïve mice using an insulin syringe. The mice were positioned under a heat 
lamp 5-10 minutes prior to injection in order to increase the size and visibility of the veins in the 
mouse tail.  
Drug Selection 
The transfected constructs all contain a pyrimethamine resistance gene, dhfr. In order to 
select for the transgenic parasites, pyrimethamine was added to the drinking water 1 day after the 
injections. Around 8-10 days post injection, the pyrimethamine-resistant parasites could be 
visualized in the blood. The blood containing transgenic parasites was harvested and the genomic 
DNA was extracted. 
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Verification of Gene Knockout 
 CRISPR/Cas9 mediated gene deletion was verified via PCR using specific primers up 
and downstream of the genomic region coding for each gene. The primers were located outside 
of the region amplified for the generation of the homology construct on the plasmids to ensure 
that there was no cross reactivity with the transfected plasmid.  
Parasite Cloning 
PCR verified KO parasites were passed into naïve mice for cloning. 2 uL of tail blood 
from the infected mice was diluted so that 1 parasite was injected intravenously into 6 naive 
mice. The cloned parasite lines were then used in all subsequent experiments and analyses.  
Growth Curves 
Blood Stages 
 For the analysis of growth in the blood stages, a predetermined number of parasites were 
injected directly into the tail vein of naïve mice. After the injection, the mice were monitored 
daily with blood smears. The blood was taken from a tail snip, smeared, fixed with methanol, 
and stained with Giemsa. The parasitemia was measured daily until the mice showed signs of 
illness. The mice were then exsanguinated and the blood was stored at -80°C. 
Mosquito Stages 
In order to assess ookinete development in vitro, ookinete cultures were set up. At 12, 18, 
and 24 hours post culture set up, samples of the cultures were smeared, fixed with methanol, 
Giemsa-stained, and visualized with light microscopy at 100X magnification. The ookinetes 
were classified as either mature or immature based on the level of development for each time 
point. 
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In order to assess ookinete development in vivo, infectious mosquito feeds were set up. 
At 12, 18, and 24 hours post infectious blood meal (PIBM), bloodfed mosquito midguts were 
dissected. Each midgut was resuspended in 5 𝜇L of PBS and smeared on a slide. Each slide was 
fixed in methanol, stained with Giemsa, and visualized with light microscopy at 100X 
magnification. The ookinetes were classified as either mature or immature based on the level of 
development for each time point. 
Sampling and Fixation of Parasites 
Blood stage parasites were isolated from tail vein blood from mice and were resuspended 
in RPMI-1640 pH 7.4 media with heparin pre-warmed to 37°C and allowed to adhere to 0.01% 
poly-L-lysine coated glass slides at 37°C. Gametogenesis was induced by resuspending tail 
blood in RPMI-1640 pH 8.2 media with heparin pre-warmed to 19°C and allowed to adhere to 
0.01% poly-L-lysine coated glass slides at 19°C. Cells were then fixed in 3% paraformaldehyde 
with 0.1% glutaraldehyde at 4°C. Cultured ookinetes were taken at experimental time points 12, 
18, and 24 hours post culture setup. RBCs were lysed with 0.17 M NH4Cl. Cells were then 
resuspended in 0.05 M Tris 0.9% NaCl pH 8.2 and allowed to adhere to 0.01% poly-L-lysine 
coated glass slides. Cells were then fixed in 4% paraformaldehyde at 4°C. Midgut ookinetes 
were isolated from dissected midguts by crushing midguts with mortar and pestle in 0.05 M Tris 
0.9% NaCl pH 8.2 and allowed to adhere to 0.01% poly-L-lysine coated glass slides.  
Immunofluorescence Labeling 
All steps were carried out at room temperature unless stated otherwise. Prepared slides 
were permeabilized with 0.1% Triton-X and blocked with 3% Bovine Serum Albumin (BSA) in 
PBS containing 0.1% Tween-20 (PBST). Slides were incubated overnight at 4°C with rabbit 
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polyclonal anti-sera containing anti-PbTrx-1 antibodies (diluted 1:500 in blocking buffer) and 
mouse monoclonal antisera containing anti-𝛼-tubulin antibodies (diluted 1:2000). Slides were 
then incubated for 1 hour with goat anti-rabbit or anti-mouse IgG Alexa Fluor 488 or 555, 
respectively, (generous gifts from Dr. Tom Sanger and Dr. Jennifer Mierisch, Loyola University 
Chicago) diluted 1:1000 with blocking buffer. Slides were sealed with glass cover slips in DAPI 
mounting medium. 
Sequence Alignments 
 Geneious v8 (Kearse et al., 2012) was used to compile all sequences that were aligned. 
The alignments were performed via MUSCLE within the Geneious software. The protein 
sequence features were determined using the InterPro database (Mulder et al., 2005). 
Statistical Analysis  
 For the blood stage growth curves, statistically significant differences were determined 
using independent t-tests using GraphPad Prism version 7 for Mac, GraphPad Software, La Jolla 
California USA www.graphpad.com. For the mosquito stage growth curves, statistically 
significant differences were determined using independent t-tests using R version 3.3.1 Vienna, 
Austria http://www.R-project.org. The level of development (mature vs. immature) of the WT 
and TrxL1 KO ookinetes were compared at each time point.
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CHAPTER III 
RESULTS 
Establishing the CRISPR/Cas9 System in Plasmodium berghei 
In order to successfully establish and utilize the CRISPR/Cas9 system in P. berghei, I 
created a new protocol using online resources and previous literature as a guide (Wagner et al. 
2014; Zhang et al. 2014; Addgene.org). I studied the CRISPR information available on the 
nonprofit plasmid repository, Addgene, to learn how to adapt the CRISPR/Cas9 technology to P. 
berghei. To generate an effective working protocol and inform my experimental design, I 
specifically used Addgene’s CRISPR tools, such as the CRISPR guide and the CRISPR 101 
eBook. 
Generation of the CRISPR/Cas9 Specific Plasmid 
As researchers had recently established the CRISPR/Cas9 system in P. falciparum 
(Wagner et al. 2014) and P. yoelii (Zhang et al. 2014), I investigated the possibility of using their 
constructs as templates. The establishment of CRISPR in P. falciparum required the co-
transfection of two plasmids, one containing the Cas9 construct, and the other containing the 
replacement cassette for the target gene (Wagner et al., 2014). This significantly decreases the 
efficiency of transfection and production of transgenic parasites. In contrast, the P. yoelii plasmid 
pYC contains all of the necessary CRISPR/Cas9 components on one large plasmid (Figure 6) 
(Zhang et al., 2014). pYC is comprised of a strong constitutive P. berghei elongation factor 1 
alpha promoter (Pbef1⍺) that drives the expression of the CRISPR-associated endonuclease
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 (Cas9) gene as well as a P. yoelii U6 small nuclear RNA promoter (PyU6) that drives the 
expression of the single guide RNA (sgRNA) scaffold. pYC also contained two drug resistance 
genes, an ampicillin resistance gene for plasmid selection in E. coli and a pyrimethamine 
resistance gene for selection of transgenic parasites. Because pYC was shown to be successful in 
establishing CRISPR in P. yoelii (Zhang et al. 2014) and only required the transfection of one 
construct, I decided to use pYC as my template. Following an inquiry with Dr. Jing Yuan from 
the Xiamen University in Xiamen, China, I received pYC as a generous gift.  
To make the CRISPR plasmid specific to P. berghei, I first needed to replace the P. yoelii 
U6 promotor with the homologous P. berghei U6 promoter. Using the BLAST sequence 
alignment too (Altshul et al. 1990), I searched the P. berghei genome for similar RNA promoters 
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and found an annotated P. berghei U6 spliceosomal RNA homolog (Otto et al., 2014). To clone 
the promoter (PbU6), I designed primers and amplified a 340 bp segment upstream of the 
transcription start site of the U6 homolog. Following sequence verification, I replaced PyU6 in 
pYC with the PbU6 to function as the new P. berghei specific promoter. I named the resulting 
plasmid, pBC (plasmid for P. berghei CRISPR/Cas9), which was used for all future 
modifications described herein.  
 
 The next step was to modify pBC to generate a trxl-1 knockout plasmid. I first identified 
a 20 bp target sequence (TS) within the trxl-1 gene (Figure 7) that ended with a PAM sequence 
of 5’ NGG 3’. In order to identify the best candidates for the TS, I utilized the ‘Find CRISPR 
sites’ function in the sequence analysis software, Geneious v8 (Kearse et al., 2012). It scans the 
gene of interest, cross references it to the Plasmodium berghei genome, and scores each 20 bp 
sequence with a specified PAM sequence of 5’ NGG 3’. The score is generated based on the 
nucleotide composition, type of PAM sequence (TGG is preferred), and the number of potential 
off-target sites in the genome. 100% is the maximum CRISPR score possible.  
From the scored sequences in the trxl-1 CDS, I chose a TS within exon 3 that resulted in 
a CRISPR score of 99.96% (TS location shown in figure 7). The short nature of the TS allowed 
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me to design it as two overlapping oligonucleotides with flanking restriction sites. I next 
attempted to clone the 20 bp TS into pBC. However, this proved to be inefficient as sequencing 
revealed that multiple copies of the TS were inserted sequentially into the plasmid (Figure 8 
LEFT).  
I repeated the cloning process while varying the concentration of the TS and sequenced 
the resulting plasmids. After three rounds of cloning and sequencing, I finally detected one 
bacterial colony containing a plasmid with only one copy of the 20 bp TS inserted directly 
upstream of the sgRNA (Figure 8 RIGHT). I named the resulting plasmid pBCT (plasmid for P. 
berghei CRISPR/Cas9 mediated trxl-1KO).  
 
For an additional level of specificity, I next designed a trxl-1 homology construct to act 
as a donor template for the homology directed repair (HDR) of the Cas9-induced double strand 
break (DSB) (See Figure 3). I generated the left and right homology arms by cloning 300-500 bp 
regions upstream and downstream of the trxl-1 coding region, respectively. In a separate vector, I 
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designed the construct around a short, random gene disrupter (IN) where the disrupter sequence 
is flanked by the right and left homology arms (Figure 9).  
The homology construct was excised and cloned into pBCT, completing my trxl-1KO 
CRISPR plasmid. pBCT, contains all of the required machinery to adapt the CRISPR/Cas9 
system to Plasmodium berghei and generate a targeted gene knock out of trxl-1. 
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 A plasmid map detailing all genetic elements of pBCT is shown in Figure 10. I have also 
included a simplified schematic demonstrating how pBCT serves as the template during HDR 
(Figure 11). 
 
Generation of Transgenic P. berghei 
To generate trxl-1KO parasites, pBCT was prepared for transfection. The blood of P. 
berghei WT-infected mice was harvested at a 1-3% parasitemia. The parasites were cultured 
overnight to allow them to mature into schizonts. The schizonts were harvested using a 
Nycodenz density gradient. pBCT was then electroporated into the purified schizonts, which 
were immediately injected into the tail veins of naïve mice. On the next day, the antimalarial 
drug, pyrimethamine (pyr) was administered in the drinking water of the mice to select for 
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transgenic parasites. I observed pyr-resistant transgenic parasites in the blood smears of mice 
eight to ten days post transfection. Once the infected mice reached a parasitemia of at least 10%, 
they were exsanguinated and the gDNA of the parasites was extracted for verification of trxl-1 
gene deletion.  
Verification of Cas9-mediated Gene Deletion of trxl-1 
For verification, I designed specific reporter primers as indicated in Figure 11 & 12. PCR 
analysis was carried out using the following DNA templates: wild type gDNA (WT), four 
samples of putative TrxL-1KO gDNA isolated from infected mice (KO1, KO2, KO3, KO4), and 
the plasmid pBCT. I also included a no template control (NTC).  
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To amplify the trxl-1 locus, primers P1 and P2 were used (Figure 12). They are located 
outside of the trxl-1 UTRs so that they recognized the gDNA template but not the homology 
construct on pBCT. The calculated amplicon size in the WT gDNA was 2.4 kb and the expected 
amplicon size for TrxL-1KO gDNA was calculated to be significantly shorter at 1.1 kb. The PCR 
results showed a clear band around 2.4 kb in the WT gDNA showing an unaltered trxl-1 gene. In 
contrast, the KO4 gDNA sample showed a band around 1.1 kb indicating successful gene 
deletion of trxl-1. My KO1 and KO2 samples did not show any clear bands. The KO3 samples 
showed bands around 2.4 kb and 1.1 kb indicating a mixed population of WT and KO parasites. 
No amplification occurred in pBCT or NTC confirming that there was no cross-reactivity with 
the plasmid or contamination of my primers, respectively. 
In addition, I checked for HDR-specific gene deletion (Figure 12). Primers P3 and P4 
were designed to hybridize with the gene disrupter sequence (IN). The primer combinations, 
P1+P4 and P2+P3, can only amplify a product if the gene disrupter within the homology 
construct was integrated into the genome replacing the trxl-1 gene. The expected amplicon size 
for P1+P4 was 500 bp and for P2+P3, it was 700 bp. For each of the TrxL-1KO gDNA samples, 
the PCR resulted in the expected bands for both of the primer sets. Concomitantly, these primer 
combinations did not produce bands in the WT gDNA, pBCT or NTC samples. Notably, the 
KO1 and KO2 samples contained the recombinant locus, even though there was no detectable 
amplification with the P1+P2 primer combination. The reason behind this is unclear. 
 To control for the integrity of all gDNA samples as well as the consistency of my 
preparation, I used primers specific to the 1-cys prx gene (gDNA control), a single copy gene 
previously characterized in our lab (Turturice et al. 2013). The expected amplicon size was 1.0 
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kb. All PCR controls reactions resulted in the amplification of the expected 1.0 kb sized band in 
all gDNA samples while no amplification in pBCT or NTC sampes occurred (Figure 12).  
 The gDNA from the transgenic KO3 parasite population was the only sample producing 
the bands that correspond to the size of the trxl-1 gene deletion, recombination via HDR, and no 
amplification of the WT locus. I therefore chose to generate clonal lines from the transgenic KO3 
sample. 
Generation of Clonal Parasite Lines 
 Parasite cloning is used to generate a population of genetically identical parasites. To this 
end, a sample of parasites from a mixed population will be serially diluted so that only a single 
parasite will be injected into the tail vein of a naïve mouse. I decided to use the KO3 population 
for parasite cloning since my PCR showed complete deletion of trxl-1. In my first attempt, I 
calculated for the injection of a single parasite directly into each of the tail veins of ten mice. 
After these attempts using one parasite per injection did not result in mouse infection, I increased 
the number to two parasites per injection. As a result, two out of ten of the mice that I injected 
showed blood stage parasites ten days post tail injection. These clones are herein referred to as 
clone 1 (c1) and clone 2 (c2).  
I extracted the genomic DNA from each of the clonal lines for verification of gene 
deletion. After initial passage, clone 1 would not increase past 5% parasitemia. With such low 
infection rates, I could not verify gene deletion and continue with this clonal line. I have stored 
c1 at -80C for later analysis. Clone 2 was able to reach a higher parasitemia of around 35%, and I 
was able to verify gene deletion via PCR. For my thesis, I used c2, referred to as the TrxL-1KO 
line, for all subsequent phenotypic analyses. 
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Analysis of TrxL-1KO Parasites 
 I investigated the potential phenotype of the TrxL-1KO parasites utilizing the following 
methods. I first compared the growth rate of the TrxL-1KO clonal line to that of its parental WT 
strain during blood stage development. Second, I examined parasite development during the 
mosquito stages. I simultaneously assessed parasite morphology via light microscopy and 
immunofluorescence microscopy. 
Trxl-1 is Not Essential in Blood Stage Development 
 
To determine whether a phenotype was present in asexual stages, 2,000 parasites of WT 
and TrxL-1KO were each injected into the tail vein of a naïve mouse. For each experiment, I 
injected three mice with WT and three mice with TrxL-1KO parasites. The parasitemia was 
measured daily by counting the number of infected red blood cells.  
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The data was compiled and the mean parasitemia over time was plotted for the WT and TrxL-
1KO (Figure 13).  
The growth curve indicated that both TrxL-1KO and WT parasites were visible in the 
blood smears by day five. The mice infected with WT began to show symptoms such as ruffled 
fur, lethargy, pale eyes, and respiratory distress, around day eight or day nine with parasitemia 
ranging from 10-15%. In contrast, the TrxL-1KO parasites seemed to show much more 
variability in growth rate and parasitemia. They reached as high as 35 – 40% parasitemia without 
showing any symptoms. These results clearly indicate that TrxL-1 is not essential in blood stage 
development. However, the variability in TrxL-1KO parasitemia made phenotypic analysis 
difficult as the data does not conclusively show that the TrxL-1KO parasites grow at a 
significantly different growth rate than WT parasites. 
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Trxl-1 Does Not Affect Morphology in Blood Stages 
 Because TrxL-1 could be potentially affecting the shape of the parasite, I examined 
parasite morphology during the blood stages. I did not find any discernable differences between 
the WT and TrxL-1KO parasites in any of the blood stages including merozoites, trophozoites, 
schizonts, and gametocytes. A comparison of the WT and TrxL1-KO parasites is shown in 
Figure 14.  
Trxl-1 is Involved in Mosquito Stage Development 
 Next, I expanded my investigation of the potential phenotype to the mosquito stages of 
development. Specifically, I examined the maturation of ookinetes within the mosquito midgut 
over the course of 24 hours. To better describe the development of the ookinetes, I used 
previously establishing maturation stages (Sinden et al. 2004) (Figure 15). 
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Five to eight day old mosquitoes were allowed to feed on WT or TrxL-1KO infected 
mice for 15 minutes. 12, 18, and 24 hours post infectious blood meal (PIBM), I dissected and 
smeared five bloodfed mosquito midguts from each cohort. I selected 12 hours PIBM as my first 
time point because the maturity level prior to this point could not be determined via light 
microscopy. Data was collected from three independent feeds with independent cohorts of 
mosquitoes and mice. The relative number of mature ookinetes was quantified for each dissected 
mosquito midgut at each time point. The percentage of mature TrxL-1KO ookinetes was 
compared with the percentage of mature WT ookinetes (Figure 16). 
 
Compared to WT ookinetes, the data shows a significant reduction in the number of 
mature TrxL-1KO ookinetes. I found that 12 hours PIBM, 76% of the wild type (WT) ookinetes 
were fully developed, while only 30% of the TrxL-1KO ookinetes were mature. At 18 hours 
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PIBM, 80% of WT ookinetes being mature, in comparison to 20% of the TrxL-1KO ookinetes 
being fully developed. By 24 hours, almost 100% of WT ookinetes were found to be mature 
while only 65% of TrxL-1 ookinetes were mature. The growth delay seen in the TrxL-1KO 
ookinetes indicates that trxl-1 does play a role in the mosquito stage development.  
 
To determine whether the TrxL-1KO ookinetes could continue to develop in the 
mosquito (see Figure 1), I dissected midguts on day 9 and day 15 to examine oocyst formation 
and removed salivary glands on day 21 to detect sporozoite formation. To visualize the oocysts, I 
stained the dissected midguts with mercurochrome and viewed them under 400X magnification. 
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I found that TrxL-1KO ookinetes were able to traverse the midgut lining and develop into 
oocysts (Figure 17A). To visualize the sporozoites, the salivary glands were dissected, crushed 
under the pressure of a coverslip, and viewed under 400X magnification. I found that the TrxL1-
KO parasites successfully developed into sporozoites as I was able to observe them flowing out 
of the salivary glands (Figure 17B).  
Once TrxL-1KO salivary gland sporozoites were confirmed, the infected mosquitoes 
were allowed to feed on naïve mice to determine whether the TrxL-1KO parasites could infect 
the mice and complete the life cycle. Twelve days post infectious feed, I found blood stage 
parasites in the mice, confirming that the TrxL-1KO sporozoites were infectious to hepatocytes 
and completed the life cycle.  
TrxL-1 Specifically Affects Ookinete Development and Morphology 
Because I hypothesized that TrxL-1 is involved in maintaining the shape of the parasite, I 
next examined the morphology of the ookinetes under light microscopy and immunofluorescence 
microscopy.  
For light microscopy, ookinetes were smeared on slides and processed as previously 
described in the materials and methods. In the smears, I found that many TrxL-1KO ookinetes 
from both the midguts and cultures possessed distinct morphological deformities (Figure 18). 
Compared to the midgut WT ookinetes (Figure 18A), some of the TrxL-1KO ookinetes were not 
able to maintain their characteristic banana-shape while others could not elongate at all (Figure 
18B). In the cultures, I also found that many TrxL-1KO ookinetes appeared to be either deflated 
with particularly thin portions of the membrane or overinflated with large, bulbous protrusions 
(Figure 18D).  
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To determine if these morphological deformities are due to the destabilization of 
microtubules, I used immunofluorescence to visualize the organization of microtubules in the 
ookinetes. To this end, I set up mosquito feeds and ookinete cultures with WT and TrxL-1KO 
parasites and prepared them for immunofluorescence labeling as detailed in the methods and 
materials. I co-labeled the parasites with anti-PbTrx-1 antibodies and anti-𝛼-tubulin antibodies 
graciously provided by Dr. Jennifer Mierisch. The tubulin antibodies localize specifically to the 
periphery of the cell as they label the microtubules. Our lab has previously shown that 
thioredoxin-1 (Trx-1) is a ubiquitously expressed protein in the cytosol of all P. berghei stages 
(Turturice et al. 2013). I therefore used anti-PbTrx-1 antibodies to mark Thioredoxin-1 as a 
cytosolic control. Parasites were imaged using confocal microscopy. To image the surface and 
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middle sections of the ookinete, separate slices of the parasites were captured via scanning 
through the sample. 
 The WT ookinetes showed distinct staining of tubulin localizing to the periphery of the 
cell while Trx-1 was observed throughout the whole cell (Figure 19). The TrxL-1KO ookinetes 
also displayed anti-PbTrx-1 staining throughout the entire length of the ookinete. However, 
unlike the WT ookinetes, the TrxL-1KO ookinetes did not show distinct staining of tubulin on 
the periphery (Figure 20).  
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In the middle and surface cross sections, tubulin was also stained throughout the whole 
cell. Interestingly, the strong staining throughout the middle section suggested that most of the 
tubulin in the ookinete was cytosolic. I did not find any stained ookinetes from the TrxL-1KO 
midguts or 24-hour culture slides. Although more imaging is required, there is a strong indication 
that the stability of the microtubules is affected by the loss of TrxL-1. 
Disruption of spm-1 in P. berghei 
In parallel with the phenotypic analysis of the TrxL-1KO parasites, I was also working on 
the construct to delete the spm-1 gene (Figure 21). I generated a spm-1 specific TS using 
Geneious as previously described for trxl-1. Because of the previous cloning problems with the 
small 20 bp TS oligonucleotide, I instead engineered the spm-1 TS into primers so that it will be 
integrated directly into the sgRNA scaffold on pBC. I used pBC as the DNA template and cloned 
the resulting TS-sgRNA amplicon into pGEM. I then cloned the spm-1 TS-sgRNA into pBC.  
 
To generate the homology construct, I used PCR to amplify the 5’ HA and 3’ HA of spm-
1. I then cloned the two homology arms into a separate vector as previously described for trxl-1. 
I named the resulting SPM-1KO plasmid pBCS for plasmid for P. berghei CRISPR/Cas9 
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mediated SPM-1KO (Figure 22). pBCS was transfected into PbWT schizonts and injected into 
naïve mice. Transgenic parasites were selected for using pyr. Drug resistant parasites were 
detected in the blood eight days post injection. The genomic DNA was extracted from five 
separate transgenic parasite populations.  
 
Verification of Cas9-mediated Gene Deletion of spm-1 
To detect successful spm-1 deletion, initial PCR analysis was conducted using primers 
specific to the 5’ HA and 3’ HA of spm-1 (Figure 23). The DNA templates used were: WT 
gDNA, five SPM-1KO (KO1-KO5) gDNA samples, pBCS, and a no template control (NTC). As 
expected, the WT gDNA generated an amplicon around 2.0 kb. Other than primer dimers, no 
amplification was observed in the NTC. Because pBCS contains the homology construct for 
spm-1, pBCS was used as a control to detect the expected amplicon size of the spm-1 deletion. 
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Three of the SPM-1KO samples (KO1, KO2, and KO5) resulted in no amplification. Two KO 
samples (KO3 and KO4) resulted in the amplification of the gDNA samples. KO3 showed a 
band around 2.0 kb which indicates that there was no gene deletion in that sample. Only one of 
the samples (KO4) contained a 1.0 kb band which indicates successful gene knockout. The KO4 
sample also showed two additional bands around 1.5 and 2.0 kb indicating a mixed population. 
Because KO4 showed gene deletion, this population was selected for cloning in order to generate 
a SPM-1KO clonal line. Once cloned, additional primers for the gene disrupter and outside of the 
5’ and 3’ HA on pBCS must be used in order to verify complete spm-1 knockout.
	
 
		
47 
Initial Analysis of SPM-1KO Parasites in Blood Stages 
 Once I confirmed the deletion of spm-1, I examined the parasites in the blood stages of 
development. Similar to the TrxL-1KO, I found that the SPM-1KO parasites were able to 
successfully infect the mice. The SPM-1KO infected mice reached parasitemias as high as 60% 
and did not show any symptoms. These results show that spm-1 is not essential for blood stage 
development. In contrast to the TrxL-1KO parasites, I found that there are morphological 
deformities in the SPM-1KO schizonts (Figure 24). In comparison to the WT schizonts that 
contain eight to twelve merozoites per cell (Figure 24 A), a portion of the SPM-1KO schizonts 
only contain four to eight merozoites (Figure 24 B). Additionally, the merozoites within each of 
the SPM-1KO schizonts appear to be more scattered and less organized than in the WT 
schizonts.  
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CHAPTER IV 
DISCUSSION 
 The purpose of this thesis was to establish the CRISPR/Cas9 gene editing system in P. 
berghei and use it to investigate the function of two novel Plasmodium genes, trxl-1 and spm-1. 
Genetic manipulation of Plasmodium remains a challenge as most methods are time consuming, 
inefficient, and expensive (Straimer et al. 2012; Wu et al. 1996). The CRISPR/Cas9 system 
represents an opportunity to reduce the cost and increase efficiency of genomic editing in the 
prominent mouse model parasite P. berghei.  
In this study, I established the CRISPR/Cas9 system in P. berghei and successfully edited 
the genome resulting in the generation of two gene KO parasite lines, TrxL-1KO and SPM-1KO. 
I found that trxl-1 is not an essential gene and is involved in ookinete development within the 
mosquito midgut. Additionally, I found that the loss of spm-1 is not lethal in asexual stages, but 
appears to be important for schizogony and gametocytogenesis in the malaria parasite. 
The establishment of the CRISPR/Cas9 system increases our ability to manipulate the P. 
berghei genome and subsequently advances the rate at which we can conduct functional studies. 
As gene deletion is often the first approach to investigating gene function, I used CRISPR/Cas9 
to knockout my genes of interest. Traditional gene knockout methods rely on the transfection of 
a plasmid, containing a drug resistance cassette, and simple homologous recombination with the 
genome to replace a targeted gene (Wu et al. 1996). This technique requires months of drug 
selection and cloning following transfection of the plasmid with highly variable success.
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In contrast, with the help of the CRISPR/Cas9 system, I generated KO parasite lines 
within just two weeks following transfection of the KO plasmids. Moreover, the resulting KO 
parasite lines did not require months of constant drug pressure because CRISPR/Cas9 produces a 
stable, targeted deletion and a quick, effective integration of the gene disrupter sequence. In 
comparison to other studies that used CRISPR/Cas9, such as the editing of the P. falciparum 
genome that required co-transfection of two plasmids (Wagner et al. 2014), I generated each 
parasite line with the transfection of one plasmid. Using a single plasmid greatly increased the 
efficiency of the generation of transgenic parasites, which subsequently improved the chance of 
successful Cas9-mediated gene KO. 
The first gene I knocked out was trxl-1. As the TrxL-1KO parasites successfully infected 
and reproduced within the mouse blood and mosquito stages, I determined that trxl-1 is not an 
essential gene. In the blood stages, I did not detect any TrxL-1KO growth phenotype, and there 
were no observable differences in TrxL-1KO parasite morphology when compared to WT 
parasites. These findings are comparable to the data from T. gondii as the researchers also did not 
detect a growth phenotype in the TgTrxL-1 knockout parasites (Liu et al., 2013). Interestingly, I 
found that although trxl-1 is dispensable for P. berghei, the knockout parasites seem to become 
less virulent as infected mice tolerated a much higher parasitemia, at times up to 45%.  
Additionally, many of the infected mice did not show any signs of illness that would be 
expected at such high parasitemia. The functional significance of this loss of virulence remains 
unknown and would be an interesting area to pursue in the future. One possible explanation is 
that the TrxL-1KO parasites do not illicit an immune response that is as strong as it is during WT 
P. berghei infection. To test for this, we can begin by checking the TrxL-1KO blood smears for 
activated white blood cells.  
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Supporting my hypothesis that trxl-1 is involved in mosquito stage development, I found 
that the growth of TrxL-1KO ookinetes is significantly delayed when compared to the WT 
ookinetes. At 18 hours PIBM, I found that approximately 80% of TrxL-1KO ookinetes were 
immature. I also observed distinct morphological deformities in the TrxL-1KO ookinetes when 
compared to WT. The normal banana-like shape of the ookinetes is not retained and in some 
cases, not established at all. As the subpellicular microtubules are known to support the 
parasite’s shape (Baum et al.2006) and the T. gondii trxl-1 homolog showed an interaction with 
microtubules, trxl-1 could be playing a role in the stabilization of the microtubules in the 
development of Plasmodium ookinetes. 
A subset of TrxL-1KO ookinetes were capable of maturing into their proper shape and 
successfully infecting the mosquito. One explanation is that there could be a compensatory 
mechanism allowing these ookinetes to function normally. In T. gondii, it was found that the 
TgTrxL-1 protein is part of a microtubule associated protein complex that consists of the 
subpellicular microtubule protein 1 (TgSPM-1), thioredoxin-like protein 2 (TgTrxL-2), and other 
novel TrxL1-associating proteins, TgTLAP-1 and TgTLAP-2 (Liu et al., 2013). However, a 
screen of the P. berghei genome revealed that Plasmodium lacks a trxl-2 homolog. Homologs for 
SPM-1, TLAP-1, and TLAP-2 are present in the rodent parasite and it is possible that they have 
the capacity to compensate for the loss of trxl-1. On the other hand, since T. gondii does not 
require an insect vector, the conditions that control microtubule stability and regulation may be 
different. Because Plasmodium parasites are exposed to the harsh conditions of the mosquito 
midgut, I would expect the proteins lining and controlling regulation of the subpellicular 
microtubules to play a more important role in the malaria parasite than in Toxoplasma.    
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A closer inspection of the Plasmodium microtubules via immunofluorescence revealed 
that the microtubules in the TrxL-1KO ookinetes appear to be less organized and are not clearly 
localized to the periphery of the cell (Figure 25). This could compromise the overall banana-
shape of the maturing ookinete. 
 
This suggests that the loss of trxl-1 prevents the localization of microtubules to the 
periphery of the cell and consequently negatively affects ookinete elongation, shape formation, 
and rate of development. While this data serves to initially characterize the molecular function of 
TrxL-1, further investigation is necessary in order to confirm the effect on microtubule 
stabilization and parasite biology. On top of additional immunofluorescence microscopy, 
viewing the parasites under a higher resolution, such as electron microscopy, would provide a 
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much more detailed look into the morphology and underlying cytoskeletal organization. Another 
approach that we could use to confirm these findings is a trxl-1 gene rescue by providing the 
parasites with a plasmid containing the functional trxl-1 gene. If normal ookinete development 
and morphology is restored, we would confirm that the phenotype we have observed is due to the 
loss of trxl-1.  
In Toxoplasma, the TrxL-1 protein was shown to indirectly associate with the 
subpellicular microtubules via an interaction with SPM-1 (Liu et al., 2013), which is why I 
decided to knockout spm-1 in P. berghei. Similar to trxl-1, I found that spm-1 is not essential for 
the development of the asexual blood stages in the mouse. However, my preliminary analysis of 
the SPM-1KO parasites showed that the SPM1-KO schizonts appear to have morphological 
differences when compared to WT. For example, no distinct equally sized merozoites can be 
identified and the number of merozoites is very low when compared to WT parasites. 
Furthermore, very few mature gametocytes have been identified in the blood smears of the SPM-
1KO infected mice. These initial observations are currently being verified and quantified in our 
lab.  
Interestingly, if spm-1 is confirmed to be involved in schizogony or gametocytogenesis, 
the overall effects of the SPM-1KO may be more detrimental than the TrxL-1KO. During 
schizogony, the pellicle of the merozoites is supported by the underlying subpellicular 
microtubules. Because spm-1 may potentially play a role in the stabilization of these 
subpellicular microtubules, pellicle formation may be negatively affected by the loss of spm-1. 
On the other hand, if gametocytogenesis is negatively affected, I would expect a more severe 
phenotype in early mosquito stages. Microtubule associated proteins, such as the STOP 
Axonemal protein (SAXO-1) in the flagellated, protozoan parasite Trypanosoma brucei 
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(Dacheux et al., 2012), have been shown to stabilize microtubules by conferring cold-resistance. 
This study also demonstrated that TbSAXO-1 is involved in flagellum motility. As Plasmodium 
experiences a temperature drop in the mosquito vector and requires the production of 
exflagellating gametocytes, spm-1 may be functioning in a similar way to TbSAXO-1. Without 
the exflagellation of gametocytes, there would be no fertilization and thus no ookinetes. If the 
ookinetes cannot develop, the life cycle ends in the mosquito, effectively blocking transmission 
to the next host. As additional analyses are required to characterize this phenotype, members of 
my lab are eagerly continuing to investigate the role of spm-1 in all stages of parasite 
development.  
Beyond discovering the cellular function of trxl-1 and spm-1, this thesis sheds light on 
the regulation of the subpellicular microtubules. In recent years, the thioredoxin system has been 
implicated in the redox regulation of important cellular pathways and structures. Certain changes 
in the redox potential of the cell, such as the production of ROS, can influence the state of 
cellular structures, including microtubules and flagella (Aksenova et al., 2001; Wakabayashi and 
King, 2006).  
Biochemical characterization of both TrxL-1 and SPM-1 proteins in our lab revealed that 
they are redox active and that each is efficiently reduced by the thioredoxin system. An 
intriguing possibility is that the association of TrxL-1 with its target proteins, such as SPM-1, 
may be redox based.  In light of these findings, it is possible that in Plasmodium, TrxL-1 and/or 
SPM-1 represent a direct link between the cellular redox regulatory system and the cytoskeleton, 
in this case the microtubules. I have included a hypothetical model representing the connection 
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between the Trx-mediated redox homeostasis of the cell and microtubule stability via the 
interactions between TrxL-1 and SPM-1 (Figure 26). 
 
With this study, I am the first to establish the CRISPR/Cas9 system in P. berghei. I 
successfully adapted this system to modify the P. berghei genome and generated two gene KO 
parasite lines with high efficiency (100% gene deletion for each trxl-1 and spm-1.) The 
functional characterization of TrxL-1 revealed that it plays a role in parasite development in the 
mosquito vector, specifically in the generation and maintenance of the banana-like ookinete 
shape. We have shown that TrxL-1 is potentially regulated by the Trx system and is involved in 
the stabilization of the subpellicular microtubules via SPM-1. Overall, this study contributes to 
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our fundamental understanding of the regulation of microtubules and reveals a potential 
mechanism for parasite development and survival in the mosquito vector.
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